Cost-effectiveness of ezetimibe coadministration in statin-treated patients not at cholesterol goal: Application to Germany, Spain and Norway

PharmacoEconomics

Volumn 22, Issue SUPPL. 3, 2004, Pages 49-61

  Cook, John R ^a   Yin, Don ^a   Alemao, Evo ^a   Davies, Glenn ^a   Krobot, Karl J ^b   Veltri, Enrico ^a   Lipka, Leslie ^a   Badia, Xavier ^c  

^a MERCK RESEARCH LABORATORIES   (United States)

^b MSD Sharp and Dohme GmbH   (Germany)

^c HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; EZETIMIBE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN; STATIN;

ADULT; AGED; ARTICLE; CORONARY ARTERY DISEASE; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DOSE CALCULATION; DRUG EFFECT; DRUG EFFICACY; FEMALE; GERMANY; HUMAN; HYPERCHOLESTEROLEMIA; LIFE EXPECTANCY; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NORWAY; PRIORITY JOURNAL; SPAIN; TITRIMETRY;

EID: 8344257993     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200422003-00006     Document Type: Article

References (45)

1. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279 (20): 1615-22
2. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335 (14): 1001-9
3. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344 (8934): 1383-9
4. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia: West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333 (20): 1301-7
5. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339 (19): 1349-57
6. Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice. European guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2003; 24: 1601-10
7. Grundy SM, Cleeman JI, Bairey Merz CN, et al., for the Coordinating Committee on of the National Cholesterol Education Program. Implications of recent trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110: 227-39
8. PROVE-IT Study Group. Comparison of intensive and moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350 (15): 1495-504
9. Nissen SE, Tuzcu EM, Schoenhagen P, et al. REVERSAL investigators. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis a randomized controlled trial. JAMA 2004; 291 (9): 1071-80
10. De Backer G. Evidence-based goals versus achievement in clinical practice in secondary prevention of coronary heart disease: findings in EUROASPIRE II. Atherosclerosis Supp 2002; 2 (4): 13-17
11. Altmann SW, Davis Jr HR, Zhu LJ, et al. Niemann-Pick C1 like 1 protein is critical for intestinal cholesterol absorption Science 2004 (Feb 20); 303: 1201-4
12. Ballantyne CM, Houri J, Notarbartolo A, et al. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation 2003; 107 (19): 2409-15
13. Davidson MH, McGarry T, Bettis R, et al. Ezetimibe coadministered with Simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol 2002; 40 (12): 2125-34
14. Gagne C, Bays HE, Weiss SR, et al. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol 2002; 90 (10): 1084-91
15. Weinstein MC, Coxson PG, Williams LW, et al. Forecasting coronary heart disease incidence, mortality, and cost: the Coronary Heart Disease Policy Model. Am J Public Health 1987; 77 (11): 1417-26
16. Goldman L, Weinstein MC, Goldman PA, et al. Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease. JAMA 1991; 265 (9): 1145-51
17. Click H, Heyse JF, Thompson D, et al. A model for evaluating the cost-effectiveness of cholesterol-lowering treatment. Int J Technol Assess Health Care 1992; 8 (4): 719-34
18. Grover SA, Abrahamowicz M, Joteph L, et al. The benefits of treating hyperlipidemia to prevent coronary heart disease: estimating changes in life expectancy and morbidity. JAMA 1992; 267 (6): 816-22
19. Wilson K, Marriott J, Fuller S, et al. A model to assess the cost effectiveness of statins in achieving the UK National Service Framework target cholesterol levels. Pharmacoeconomics 2003; 21 Suppl. 1; 1-11
20. Jonsson B, Johannesson M, Kjekshus J, et al. Cost-etfectiveness of cholesterol lowering: results from the Scandinavian Simvastatin Survival Study (4S). Eur Heart J 1996; 17 (7): 1001-7
21. Johannesson M, Jonsson B, Kjekshus J, et al. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease: Scandinavian Simvastatin Survival Study Group. N Engl J Med 1997; 336 (5): 332-6
22. Caro J, Klittich W, McGuire A, et al. International economic analysis of primary prevention of cardiovascular disease with pravastatin in WOSCOPS: West of Scotland Coronary Prevention Study. Eur Heart J 1999; 20 (4): 263-8
23. Cook JR, Yin D, Alemao D, et al. Development and validation of a model to project the long-term benefit and cost of alternative lipid-lowering strategies in patients with hypercholesterolaemia. Pharmacoeconomics 2004 ((this suppl., details to come))
24. Anderson KM, Odell PM, Wilson PW, et al. Cardiovascular disease risk profiles. Am Heart J 1991; 121 (1 Pt 2): 293-8
25. D'Agostino RB, Russell MW, Huse DM, et al. Primary and subsequent coronary risk appraisal: new results from the Framingham study. Am Heart J 2000; 139 (2 Pt 1): 272-81
26. Statistisches Bundesamt. Todesursachenstatistik 2000. Wiesbaden, Germany: 2000
27. Norwegian Statistical Yearbook 2002. Statistics Norway, Oslo 2002
28. Institute Nacional de Estadísticao Defunciones segín la causa de muerte 2001. Available at http://www.ine.es. Accessed February 10, 2004.
29. Krobot KJ, Yin DD, Alemao E, et al. Real-world effectiveness of lipid-lowering therapy in male and female outpatients with CHD: relation to pretreatment LDL-cholesterol, pretreatment CHD risk, and other factors. Eur J Cardiovasc Prev Rehabil. In press
30. Garcia Ruiz FJ, Marín Ibáñez A, Pérez- Jiménez F, et al. Current lipid management and low cholesterol goal attainment in common daily practice in Spain: the REALITY Study. Pharmacoeconomics 2004
31. Ose L, Skjeldestad FE, Bakken IJ, et al. Current management of hyperlipidemia in Norway and factors associated with cholesterol goal attainment. Atherosclerosis Suppl. 2004; 5 (1): 141
32. Gohlke H, Kubler W, Mathes P, et al. Recommendations for comprehensive risk reduction for patients with coronary heart disease, vascular diseases and diabetes. Distributed by the leadership of the German Society of Cardiology, Heart and Vascular Research. Produced by request of the Committee of Clinical Cardiology by the Prevention Project Group. Z Kardiol 2002; 91 Suppl. 2: 61-2
33. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106 (3); 3143-421
34. Second Joint Task Force of European and other Societies. Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on coronary prevention. Eur Heart J 2004; 19 (10): 1434-503
35. Stein E. Stender S, Mata P, et al. Ezetimibe Study Group. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co administered with atorvastatin. Am Heart J. 2004; 148 (3): 447-55.
36. Dobs AS, Guyton JR, McClusky D, et al. Coadministration of ezetimibe with simvastatin. J Am Coll Cardiol 2004; 41 (6): 227A
37. Activity based financing with price list [in Norwegian]. Oslo: Ministry of Health, 2003
38. Cost and benefits of replacing thrombolysis by PCI for acute myocardial infarction [in Norwegian]. Oslo: The Norwegian Centre for Health Technology Assessment, 2004
39. Gold MR, Siegel JE, Russell LB, et al., editors. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996: 233
40. Palmer SJ, Brady AJ, Ratcliffe AE. The cost-effectiveness of a new statin (rosuvastatin) in the UK NHS. Int J Clin Pract 2003; 57 (9): 792-800
41. Attanasio E, Russo P, Allen SE. Cost-minimization analysis of simvastatin versus atorvastatin for maintenance therapy in patients with coronary or peripheral vascular disease. Clin Ther 2001; 23 (2): 276-83
42. Morrison A, Glassberg H. Determinants of the cost-effectiveness of statins. J Manag Care Pharm 2003; 9 (6): 544-51
43. Haq IU, Ramsay LE, Yeo WW, et al. Is the Framingham risk function valid for northern European populations? A comparison of methods for estimating absolute coronary risk in high risk men. Heart 1999; 81 (1): 40-6
44. Marrugat J, Solanas P, D'Agostino R, et al. Coronary risk estimation in Spain using a calibrated Framingham function [in Spanish]. Rev Esp Cardiol 2003; 56 (3): 253-61
45. Marrugat J, D'Agostino R, Sullivan L, et al. An adaptation of the Framingham coronary heart disease risk function to European Mediterranean areas. J Epidemiol Commun Health 2003; 57 (8): 634-8